Regeneron Pharmaceuticals on Monday said its COVID-19 antibody drug reduced the risk of symptomatic infections by 81 percent in a phase-three trial of the therapy.The company said it will ask the U.S
China's CanSino Biologics Inc said on Wednesday its COVID-19 vaccine was approved in Mexico for emergency use for people of 18 years of age or older.On Monday, Pakistan said CanSinoBio's vaccine show
China's CanSino Biologics Inc.'s (CanSinoBIO) COVID-19 vaccine showed 74.8 percent efficacy in preventing symptomatic cases and a 100-percent success rate in stopping severe disease among Pakistanis
简体中文
